Summary
DAP Chart
Danaher Partners With AstraZeneca to Support Precision Medicine
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON , May 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments. "Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said Julie Sawyer Montgomery, Danaher Executive Vice President.
CVS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Corporation Dividends
 DAP 2 months ago | Other | €0.28 Per Share |
| DAP 5 months ago | Other | €0.24 Per Share |
| DAP 8 months ago | Other | €0.24 Per Share |
| DAP 11 months ago | Other | €0.24 Per Share |
| DAP 27 Mar 2024 | Other | €0.24 Per Share |
Danaher Corporation Earnings
| 21 Jul 2025 (47 Days) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | - EPS |
| 22 Oct 2024 Date | | - Cons. EPS | - EPS |
| 23 Jul 2024 Date | | - Cons. EPS | - EPS |
| DAP 2 months ago | Other | €0.28 Per Share |
| DAP 5 months ago | Other | €0.24 Per Share |
| DAP 8 months ago | Other | €0.24 Per Share |
| DAP 11 months ago | Other | €0.24 Per Share |
| DAP 27 Mar 2024 | Other | €0.24 Per Share |
| 21 Jul 2025 (47 Days) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | - EPS |
| 22 Oct 2024 Date | | - Cons. EPS | - EPS |
| 23 Jul 2024 Date | | - Cons. EPS | - EPS |
Danaher Corporation (DAP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Danaher Corporation ever had a stock split?
Danaher Corporation Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Mr. Rainer M. Blair CEO | XMUN Exchange | US2358511028 ISIN |
| US Country | 61,000 Employees | 28 Mar 2025 Last Dividend | 2 Oct 2023 Last Split | 5 Jan 1979 IPO Date |
Overview
Danaher Corporation is a global powerhouse in the design, manufacturing, and marketing of a vast array of professional, medical, industrial, and commercial products and services. With its inception in 1969 and a significant rebranding in 1984, where it transitioned from Diversified Mortgage Investors, Inc. to Danaher Corporation, the company has established a formidable presence in various sectors. Headquartered in Washington, D.C., Danaher stands out through its commitment to innovation, excellence, and enhancing the quality of life worldwide.
Products and Services
- Biotechnology: Danaher's biotechnology segment is a provider of bioprocess technologies, consumables, and services enhancing the development and manufacture of therapeutics. This includes cell line and cell culture media development, chromatography resins, filtration technologies, aseptic fill-finish solutions, single-use hardware, and comprehensive services aimed at setting up full manufacturing suites.
- Life Sciences: This segment delivers a wide range of products including mass spectrometers, flow cytometry, genomics solutions, lab automation instruments, centrifugation, liquid handling automation instruments, antibodies and reagents, particle counting and characterization tools, microscopes, and protein consumables. Among the notable brands under the Life Sciences segment are ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX, each providing specialized products for genomic medicines and industrial filtration.
- Diagnostics: Danaher’s diagnostics sector offers a comprehensive range of chemistry, immunoassay, microbiology, automation systems, molecular diagnostics, acute care, and pathology diagnostics products. Aimed at hospitals, physicians' offices, reference laboratories, and other critical care settings, this segment ensures the delivery of clinical instruments, reagents, consumables, software, and dedicated services to support critical diagnostics.
Contact Information
